Cargando…

A heparin–rosuvastatin-loaded P(LLA-CL) nanofiber-covered stent inhibits inflammatory smooth-muscle cell viability to reduce in-stent stenosis and thrombosis

BACKGROUND: An endovascular covered-stent has unique advantages in treating complex intracranial aneurysms; however, in-stent stenosis and late thrombosis have become the main factors affecting the efficacy of covered-stent treatment. Smooth-muscle-cell phenotypic modulation plays an important role...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yingjun, Liu, Peixi, Song, Yaying, Li, Sichen, Shi, Yuan, Quan, Kai, Yu, Guo, Li, Peiliang, An, Qingzhu, Zhu, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8086342/
https://www.ncbi.nlm.nih.gov/pubmed/33926468
http://dx.doi.org/10.1186/s12951-021-00867-8
_version_ 1783686503207010304
author Liu, Yingjun
Liu, Peixi
Song, Yaying
Li, Sichen
Shi, Yuan
Quan, Kai
Yu, Guo
Li, Peiliang
An, Qingzhu
Zhu, Wei
author_facet Liu, Yingjun
Liu, Peixi
Song, Yaying
Li, Sichen
Shi, Yuan
Quan, Kai
Yu, Guo
Li, Peiliang
An, Qingzhu
Zhu, Wei
author_sort Liu, Yingjun
collection PubMed
description BACKGROUND: An endovascular covered-stent has unique advantages in treating complex intracranial aneurysms; however, in-stent stenosis and late thrombosis have become the main factors affecting the efficacy of covered-stent treatment. Smooth-muscle-cell phenotypic modulation plays an important role in late in-stent stenosis and thrombosis. Here, we determined the efficacy of using covered stents loaded with drugs to inhibit smooth-muscle-cell phenotypic modulation and potentially lower the incidence of long-term complications. METHODS: Nanofiber-covered stents were prepared using coaxial electrospinning, with the core solution prepared with 15% heparin and 20 µM rosuvastatin solution (400: 100 µL), and the shell solution prepared with 120 mg/mL hexafluoroisopropanol. We established a rabbit carotid-artery aneurysm model, which was treated with covered stents. Angiography and histology were performed to evaluate the therapeutic efficacy and incidence rate of in-stent stenosis and thrombosis. Phenotype, function, and inflammatory factors of smooth-muscle cells were studied to explore the mechanism of rosuvastatin action in smooth-muscle cells. RESULT: Heparin–rosuvastatin-loaded nanofiber scaffold mats inhibited the proliferation of synthetic smooth-muscle cells, and the nanofiber-covered stent effectively treated aneurysms in the absence of notable in-stent stenosis. Additionally, in vitro experiments showed that rosuvastatin inhibited the smooth-muscle-cell phenotypic modulation of platelet-derived growth factor-BB induction and decreased synthetic smooth-muscle-cell viability, as well as secretion of inflammatory cytokines. CONCLUSION: Rosuvastatin inhibited the abnormal proliferation of synthetic smooth-muscle cells, and heparin–rosuvastatin-loaded covered stents reduced the incidence of stenosis and late thrombosis, thereby improving the healing rates of stents used for aneurysm treatment. GRAPHIC ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12951-021-00867-8.
format Online
Article
Text
id pubmed-8086342
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-80863422021-04-30 A heparin–rosuvastatin-loaded P(LLA-CL) nanofiber-covered stent inhibits inflammatory smooth-muscle cell viability to reduce in-stent stenosis and thrombosis Liu, Yingjun Liu, Peixi Song, Yaying Li, Sichen Shi, Yuan Quan, Kai Yu, Guo Li, Peiliang An, Qingzhu Zhu, Wei J Nanobiotechnology Research BACKGROUND: An endovascular covered-stent has unique advantages in treating complex intracranial aneurysms; however, in-stent stenosis and late thrombosis have become the main factors affecting the efficacy of covered-stent treatment. Smooth-muscle-cell phenotypic modulation plays an important role in late in-stent stenosis and thrombosis. Here, we determined the efficacy of using covered stents loaded with drugs to inhibit smooth-muscle-cell phenotypic modulation and potentially lower the incidence of long-term complications. METHODS: Nanofiber-covered stents were prepared using coaxial electrospinning, with the core solution prepared with 15% heparin and 20 µM rosuvastatin solution (400: 100 µL), and the shell solution prepared with 120 mg/mL hexafluoroisopropanol. We established a rabbit carotid-artery aneurysm model, which was treated with covered stents. Angiography and histology were performed to evaluate the therapeutic efficacy and incidence rate of in-stent stenosis and thrombosis. Phenotype, function, and inflammatory factors of smooth-muscle cells were studied to explore the mechanism of rosuvastatin action in smooth-muscle cells. RESULT: Heparin–rosuvastatin-loaded nanofiber scaffold mats inhibited the proliferation of synthetic smooth-muscle cells, and the nanofiber-covered stent effectively treated aneurysms in the absence of notable in-stent stenosis. Additionally, in vitro experiments showed that rosuvastatin inhibited the smooth-muscle-cell phenotypic modulation of platelet-derived growth factor-BB induction and decreased synthetic smooth-muscle-cell viability, as well as secretion of inflammatory cytokines. CONCLUSION: Rosuvastatin inhibited the abnormal proliferation of synthetic smooth-muscle cells, and heparin–rosuvastatin-loaded covered stents reduced the incidence of stenosis and late thrombosis, thereby improving the healing rates of stents used for aneurysm treatment. GRAPHIC ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12951-021-00867-8. BioMed Central 2021-04-29 /pmc/articles/PMC8086342/ /pubmed/33926468 http://dx.doi.org/10.1186/s12951-021-00867-8 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Liu, Yingjun
Liu, Peixi
Song, Yaying
Li, Sichen
Shi, Yuan
Quan, Kai
Yu, Guo
Li, Peiliang
An, Qingzhu
Zhu, Wei
A heparin–rosuvastatin-loaded P(LLA-CL) nanofiber-covered stent inhibits inflammatory smooth-muscle cell viability to reduce in-stent stenosis and thrombosis
title A heparin–rosuvastatin-loaded P(LLA-CL) nanofiber-covered stent inhibits inflammatory smooth-muscle cell viability to reduce in-stent stenosis and thrombosis
title_full A heparin–rosuvastatin-loaded P(LLA-CL) nanofiber-covered stent inhibits inflammatory smooth-muscle cell viability to reduce in-stent stenosis and thrombosis
title_fullStr A heparin–rosuvastatin-loaded P(LLA-CL) nanofiber-covered stent inhibits inflammatory smooth-muscle cell viability to reduce in-stent stenosis and thrombosis
title_full_unstemmed A heparin–rosuvastatin-loaded P(LLA-CL) nanofiber-covered stent inhibits inflammatory smooth-muscle cell viability to reduce in-stent stenosis and thrombosis
title_short A heparin–rosuvastatin-loaded P(LLA-CL) nanofiber-covered stent inhibits inflammatory smooth-muscle cell viability to reduce in-stent stenosis and thrombosis
title_sort heparin–rosuvastatin-loaded p(lla-cl) nanofiber-covered stent inhibits inflammatory smooth-muscle cell viability to reduce in-stent stenosis and thrombosis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8086342/
https://www.ncbi.nlm.nih.gov/pubmed/33926468
http://dx.doi.org/10.1186/s12951-021-00867-8
work_keys_str_mv AT liuyingjun aheparinrosuvastatinloadedpllaclnanofibercoveredstentinhibitsinflammatorysmoothmusclecellviabilitytoreduceinstentstenosisandthrombosis
AT liupeixi aheparinrosuvastatinloadedpllaclnanofibercoveredstentinhibitsinflammatorysmoothmusclecellviabilitytoreduceinstentstenosisandthrombosis
AT songyaying aheparinrosuvastatinloadedpllaclnanofibercoveredstentinhibitsinflammatorysmoothmusclecellviabilitytoreduceinstentstenosisandthrombosis
AT lisichen aheparinrosuvastatinloadedpllaclnanofibercoveredstentinhibitsinflammatorysmoothmusclecellviabilitytoreduceinstentstenosisandthrombosis
AT shiyuan aheparinrosuvastatinloadedpllaclnanofibercoveredstentinhibitsinflammatorysmoothmusclecellviabilitytoreduceinstentstenosisandthrombosis
AT quankai aheparinrosuvastatinloadedpllaclnanofibercoveredstentinhibitsinflammatorysmoothmusclecellviabilitytoreduceinstentstenosisandthrombosis
AT yuguo aheparinrosuvastatinloadedpllaclnanofibercoveredstentinhibitsinflammatorysmoothmusclecellviabilitytoreduceinstentstenosisandthrombosis
AT lipeiliang aheparinrosuvastatinloadedpllaclnanofibercoveredstentinhibitsinflammatorysmoothmusclecellviabilitytoreduceinstentstenosisandthrombosis
AT anqingzhu aheparinrosuvastatinloadedpllaclnanofibercoveredstentinhibitsinflammatorysmoothmusclecellviabilitytoreduceinstentstenosisandthrombosis
AT zhuwei aheparinrosuvastatinloadedpllaclnanofibercoveredstentinhibitsinflammatorysmoothmusclecellviabilitytoreduceinstentstenosisandthrombosis
AT liuyingjun heparinrosuvastatinloadedpllaclnanofibercoveredstentinhibitsinflammatorysmoothmusclecellviabilitytoreduceinstentstenosisandthrombosis
AT liupeixi heparinrosuvastatinloadedpllaclnanofibercoveredstentinhibitsinflammatorysmoothmusclecellviabilitytoreduceinstentstenosisandthrombosis
AT songyaying heparinrosuvastatinloadedpllaclnanofibercoveredstentinhibitsinflammatorysmoothmusclecellviabilitytoreduceinstentstenosisandthrombosis
AT lisichen heparinrosuvastatinloadedpllaclnanofibercoveredstentinhibitsinflammatorysmoothmusclecellviabilitytoreduceinstentstenosisandthrombosis
AT shiyuan heparinrosuvastatinloadedpllaclnanofibercoveredstentinhibitsinflammatorysmoothmusclecellviabilitytoreduceinstentstenosisandthrombosis
AT quankai heparinrosuvastatinloadedpllaclnanofibercoveredstentinhibitsinflammatorysmoothmusclecellviabilitytoreduceinstentstenosisandthrombosis
AT yuguo heparinrosuvastatinloadedpllaclnanofibercoveredstentinhibitsinflammatorysmoothmusclecellviabilitytoreduceinstentstenosisandthrombosis
AT lipeiliang heparinrosuvastatinloadedpllaclnanofibercoveredstentinhibitsinflammatorysmoothmusclecellviabilitytoreduceinstentstenosisandthrombosis
AT anqingzhu heparinrosuvastatinloadedpllaclnanofibercoveredstentinhibitsinflammatorysmoothmusclecellviabilitytoreduceinstentstenosisandthrombosis
AT zhuwei heparinrosuvastatinloadedpllaclnanofibercoveredstentinhibitsinflammatorysmoothmusclecellviabilitytoreduceinstentstenosisandthrombosis